Previous close | 0.1104 |
Open | 0.0984 |
Bid | 0.1070 x 460000 |
Ask | 0.1090 x 450000 |
Day's range | 0.0984 - 0.1070 |
52-week range | 0.0840 - 0.3320 |
Volume | |
Avg. volume | 242 |
Market cap | 17.164M |
Beta (5Y monthly) | 1.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PARIS, April 30, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today reported its consolidated results for the fiscal year ending December 31, 2023.
PARIS, February 06, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces a reduction of the par value of its shares.
PARIS, January 31, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO)